Related Experiment Video
Updated: Apr 11, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
Andrew Ustianowski1, Joop E Arends
1Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK, andrew.ustianowski@pat.nhs.uk.
Abstract:
Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies-informing on its efficacy, use, and adverse features-and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008-focusing on efficacy, side effects, and utility.
More Related Videos
Related Concept Videos
Retroviruses
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Teratogenicity
Therapeutic Drug Monitoring: Affecting Factors

